Skip to content

Bicara Therapeutics BCAX Balance Sheet Statement

FY'25FY'24FY'23
$96.69M-80.3%$489.71M+113%$230.44M+5,442%
$318.12M$0
$422.05M-16.0%$502.53M+117%$231.07M
$330K+113%$155K-23.3%$202K
$430.99M-15.5%$510M+118%$233.98M
$28.95M+60.9%$17.99M+19.3%$15.09M
$29.54M+63.0%$18.12M+17.1%$15.47M
500M+7,142,757%7K+250%2K
-$358.97M-62.4%-$221.02M-44.4%-$153.02M
$401.45M-18.4%$491.88M+431%-$148.77M-50.6%
$430.99M-15.5%$510M+118%$233.98M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Bicara Therapeutics's total assets?
Bicara Therapeutics (BCAX) holds $553.6M in total assets, up 15.8% year over year.
How much debt does Bicara Therapeutics have?
Bicara Therapeutics carries $1.4M in total debt against $514.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Bicara Therapeutics have?
Bicara Therapeutics holds $323.5M in cash and equivalents.
Can Bicara Therapeutics cover its short-term obligations?
Its current ratio is 13.85 — current assets exceed current liabilities.
Where does Bicara Therapeutics's balance sheet data come from?
Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.